ClinicalTrials.gg
CompletedNCT01154127GLOW3Updated May 7, 2012Results posted

Effect of NVA237 on Exercise Endurance in Patients With Chronic Obstructive Pulmonary Disease (COPD)

A Phase 3 interventional study of NVA237 and Placebo in Chronic Obstructive Pulmonary Disease, sponsored by Novartis Pharmaceuticals. Completed at 10 sites in 5 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2012-05-07.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
108
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive — 2 open to participants now, 2 under way, 1 of them phase 3. Glycopyrrolate · Pulmonary Disease, Chronic Obstructive.

Enrollment
41st of 73
108 · median 152
Started
2010
with 4 others
Phase 3
33 of 73
1 open now
Registered
13th of 73
by date
Lead sponsor
19 of 73
Novartis Pharmaceuticals

Among the 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive, this one is the 41st largest by enrollment, is one of 5 that started in 2010, is one of 33 in phase 3, and was the 13th registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

2 of the 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About glycopyrrolate

Glycopyrrolate: first FDA approval 1961 (ROBINUL FORTE), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive, or all of them as a file.
02

Study summary

The ability for patients with COPD to exercise is limited due to the deterioration of their lung function. NVA237 is being developed to treat COPD. This study is designed to look at how well NVA237 improves the ability to exercise in patients with moderate to severe COPD.

03

Conditions studied

  • Chronic Obstructive Pulmonary Disease

Keywords

  • NVA237
  • COPD
  • bronchodilator
  • exercise endurance
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients who signed an Form prior to initiation of any study-related procedure
  • Patients with moderate to severe stable (clinical diagnosis in compliance with GOLD 2008)
  • Current or ex-smokers with a smoking history ≥ 10 pack years. (Ten pack-years were defined as 20 cigarettes a day for 10 years, or 10 cigarettes a day for 20 years etc.).
  • Patients with a post-bronchodilator ≥ 40 and \< 70% of the predicted normal, and postbronchodilator FEV1/FVC \< 0.7 during screening. (Post referred to the highest post-bronchodilator value after inhalation of 80 μg ipratropium bromide)
  • Increase in FEV1 from pre- to post-bronchodilator assessment of ≥ 5%

Exclusion criteria

Exclusion Criteria:

  • Pregnant women or nursing mothers
  • Women of
  • Patients who had a exacerbation (whether hospitalized or not) in the 6 weeks prior to Visit 1 or between Visit 1 and Visit 4
  • Patients who had a lower respiratory tract infection in the 6 weeks prior to Visit 1
  • Patients requiring long term oxygen therapy on a daily basis for chronic hypoxemia
  • Patients with resting (5 min) oxygen SaO2 (or SpO2) saturation on room air of \< 85%
  • Patients with a maximum workload (Wmax) value \< 20 W (as determined by the incremental cycle endurance test) at Visit 2.
  • Patients whose exercise endurance time at sub-maximal workload was above 25 min at baseline
  • Patients with a abnormality on the screening or baseline who in the judgment of the investigator would have been at potential risk if enrolled into the study
  • Patients with a history of long syndrome or whose QTc was prolonged (> 450 ms for males and > 470 ms females) at screening (Fredericia's correction)

Other protocol-defined inclusion/exclusion criteria applied

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
108 participants (actual)

Study arms

  • Experimental
    NVA237 followed by Placebo

    Period 1: 50 μg NVA237 via NEOHALER inhaler device for 21 days Period 2: Matching placebo via NEOHALER inhaler device for 21 days The washout period ran for 14 to 28 days between treatment periods. Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. Salbutamol (albuterol) was used as rescue medication throughout the study.

    Drug: NVA237 · Drug: Placebo

  • Experimental
    Placebo followed by NVA237

    Period 1: Matching placebo of NVA237 via NEOHALER inhaler device for 21 days Period 2: 50 μg NVA237 via NEOHALER inhaler device for 21 days The washout period ran for 14 to 28 days between treatment periods. Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. Salbutamol (albuterol) was used as rescue medication throughout the study.

    Drug: NVA237 · Drug: Placebo

Interventions

  • DrugNVA237

    50 μg via NEOHALER inhaler device single dose dry powder inhaler (SDDPI) once daily

  • DrugPlacebo

    Matching placebo via NEOHALER inhaler device single dose dry powder inhaler (SDDPI) once daily

06

What researchers measure

Primary outcomes

  1. Exercise Endurance Time During a Sub-maximal Constant-load Cycle Ergometry Test (SMETT) After 3 Weeks (Day 21) of Treatment

    SMETT is an exercise procedure where the patient cycles at 80% of the maximum workload (Wmax )value achieved at the Incremental exercise test. During this test, the patient will cycle at a constant load. Exercise endurance time was from commencement of loaded pedaling to stopping exercise. The analysis-of covariance model included the sequence, period, and treatment as fixed factors, the baseline value as covariate and the patient as a random effect.

    Time frame: Day 21

Secondary outcomes

  1. Isotime Inspiratory Capacity (IC) During Sub-maximal Constant-load Cycle Ergometry Test (SMETT) After 3 Weeks of Treatment

    Isotime is the last matching timepoint in the submaximal exercise tolerance test (SMETT) at which for both periods the patient has a test result. The analysis-of covariance model included the sequence, period, and treatment as fixed factors, the baseline value as covariate and the patient as a random effect.

    Time frame: Day 21

  2. Inspiratory Capacity (IC) at Rest (1 Hour Post Dose) and at Peak (End of Exercise) During Sub-maximal Constant-load Cycle Ergometry Test (SMETT) After 3 Weeks of Treatment

    IC at peak was observed using spirometry. However, two different methodologies (whole body plethysmography (Bodybox) and spirometry) were used to observe IC at rest. The analysis of covariance model included the sequence, period, and treatment as fixed factors, the baseline value as covariate and the patient as a random effect.

    Time frame: Day 21

  3. Peak and Trough (24 h Post Dose) Forced Expiratory Volume in 1 Second (FEV1) and Forced Vital Capacity (FVC)

    FEV1 is the amount of air that can be exhaled in one second. FEV1 was measured with spirometry conducted according to internationally accepted standards. FVC is the volume of air that can forcibly be blown out after full inspiration and is used in spirometry tests. The trough effects of Day 1 treatment are derived from values prior to morning dosing on the next treatment day (Day 2 of the corresponding period). The analysis-of covariance model included the sequence, period, and treatment as fixed factors, the baseline value as covariate and the patient as a random effect.

    Time frame: Day 21

  4. Slow Vital Capacity (SVC) and Total Lung Capacity (TLC)

    Vital Capacity is the amount of air that can be forcibly exhaled from the lungs after a full inhalation. Slow Vital Capacity (SVC) test is performed by having the patient slowly and completely blow out all of the air from their lungs. Total Lung Capacity (TLC) is the best vital capacity plus residual volume. Whole body plethysmography (Bodybox) was used to measure SVC and TLC. The trough effects of Day 1 treatment are derived from values prior to morning dosing on the next treatment day (Day 2 of the corresponding period).

    Time frame: Day 21

  5. Specific Airways Conductance (SGaw)

    SGaw is a measure of how hard it is to get air into the lungs, measured by (Sec(-1)\*kP). Whole body plethysmography (Bodybox) was used to measure SGaw. The analysis-of covariance model included the sequence, period, and treatment as fixed factors, the baseline value as covariate and the patient as a random effect.

    Time frame: Day 21

  6. Exertional Dyspnea (Borg CR10 Scale) During Sub-maximal Constant-load Cycle Ergometry Test (SMETT) After 3 Weeks Treatment

    The Borg CR10 Scale consists of 12-point score that the patients pointed to so as to indicate their level of dyspnea before and during exercise testing (where 0 indicates no breathlessness at all and 12 indicates maximum breathlessness). A reduction in this score indicates an improvement. The analysis-of covariance model included the sequence, period, and treatment as fixed factors, the baseline value as covariate and the patient as a random effect.

    Time frame: Day 21

  7. Leg Discomfort (Borg CR10 Scale) During Sub-maximal Constant-load Cycle Ergometry Test (SMETT) After 3 Weeks Treatment

    The modified Borg CR10 Scale consists of 12-point score that the patients pointed to so as to indicate their level of leg discomfort before and during exercise testing (where 0 indicates no breathlessness at all and 12 indicates maximum breathlessness). A reduction in this score indicates an improvement. The analysis-of covariance model included the sequence, period, and treatment as fixed factors, the baseline value as covariate and the patient as a random effect.

    Time frame: Day 21

  8. Exercise Endurance Time During a Sub-maximal Constant-load Cycle Ergometry Test (SMETT) on Treatment Day 1

    SMETT is an exercise procedure where the patient cycles at 80% of the maximum workload (Wmax )value achieved at the Incremental exercise test. During this test, the patient will cycle at a constant load. Exercise endurance time was from commencement of loaded pedaling to stopping exercise. The analysis-of covariance model included the sequence, period, and treatment as fixed factors, the baseline value as covariate and the patient as a random effect.

    Time frame: Day 1

07

Results

Posted May 7, 2012

Participant flow

Period 1 (21 Days)
Participant flow — Period 1 (21 Days)
MilestoneNVA237 Followed by PlaceboPlacebo Followed by NVA237
Started5553
Completed5247
Not completed36
Withdrew: Adverse event34
Withdrew: Withdrawal by subject02
Washout (14 - 28 Days)
Participant flow — Washout (14 - 28 Days)
MilestoneNVA237 Followed by PlaceboPlacebo Followed by NVA237
Started5247
Completed4947
Not completed30
Withdrew: Adverse event20
Withdrew: Abnormal test procedure10
Period 2 (21 Days)
Participant flow — Period 2 (21 Days)
MilestoneNVA237 Followed by PlaceboPlacebo Followed by NVA237
Started4947
Completed4946
Not completed01
Withdrew: Protocol deviation01

Outcome measures

PrimaryExercise Endurance Time During a Sub-maximal Constant-load Cycle Ergometry Test (SMETT) After 3 Weeks (Day 21) of Treatment

SMETT is an exercise procedure where the patient cycles at 80% of the maximum workload (Wmax )value achieved at the Incremental exercise test. During this test, the patient will cycle at a constant load. Exercise endurance time was from commencement of loaded pedaling to stopping exercise. The analysis-of covariance model included the sequence, period, and treatment as fixed factors, the baseline value as covariate and the patient as a random effect.

Time frame:
Day 21
Reported as:
Least squares mean · seconds
Exercise Endurance Time During a Sub-maximal Constant-load Cycle Ergometry Test (SMETT) After 3 Weeks (Day 21) of Treatment
secondsNVA237Placebo
Exercise Endurance Time During a Sub-maximal Constant-load Cycle Ergometry Test (SMETT) After 3 Weeks (Day 21) of Treatment505.63 (466.59 to 544.68)416.70 (377.76 to 455.64)
SecondaryIsotime Inspiratory Capacity (IC) During Sub-maximal Constant-load Cycle Ergometry Test (SMETT) After 3 Weeks of Treatment

Isotime is the last matching timepoint in the submaximal exercise tolerance test (SMETT) at which for both periods the patient has a test result. The analysis-of covariance model included the sequence, period, and treatment as fixed factors, the baseline value as covariate and the patient as a random effect.

Time frame:
Day 21
Reported as:
Least squares mean · Liters
Isotime Inspiratory Capacity (IC) During Sub-maximal Constant-load Cycle Ergometry Test (SMETT) After 3 Weeks of Treatment
LitersNVA237Placebo
Isotime Inspiratory Capacity (IC) During Sub-maximal Constant-load Cycle Ergometry Test (SMETT) After 3 Weeks of Treatment2.22 (2.15 to 2.31)2.02 (1.95 to 2.08)
SecondaryInspiratory Capacity (IC) at Rest (1 Hour Post Dose) and at Peak (End of Exercise) During Sub-maximal Constant-load Cycle Ergometry Test (SMETT) After 3 Weeks of Treatment

IC at peak was observed using spirometry. However, two different methodologies (whole body plethysmography (Bodybox) and spirometry) were used to observe IC at rest. The analysis of covariance model included the sequence, period, and treatment as fixed factors, the baseline value as covariate and the patient as a random effect.

Time frame:
Day 21
Reported as:
Least squares mean · Litres
Inspiratory Capacity (IC) at Rest (1 Hour Post Dose) and at Peak (End of Exercise) During Sub-maximal Constant-load Cycle Ergometry Test (SMETT) After 3 Weeks of Treatment
LitresNVA237Placebo
IC at peak (Spirometry), Day 21 (n = 93, 90)2.22 (2.16 to 2.28)2.03 (1.97 to 2.10)
IC at rest (Bodybox) Day 21 (n= 97, 96)2.49 (2.40 to 2.59)2.26 (2.17 to 2.35)
IC at rest (Spirometry), Day 21 (n= 98, 96)2.39 (2.33 to 2.45)2.17 (2.10 to 2.23)
SecondaryPeak and Trough (24 h Post Dose) Forced Expiratory Volume in 1 Second (FEV1) and Forced Vital Capacity (FVC)

FEV1 is the amount of air that can be exhaled in one second. FEV1 was measured with spirometry conducted according to internationally accepted standards. FVC is the volume of air that can forcibly be blown out after full inspiration and is used in spirometry tests. The trough effects of Day 1 treatment are derived from values prior to morning dosing on the next treatment day (Day 2 of the corresponding period). The analysis-of covariance model included the sequence, period, and treatment as fixed factors, the baseline value as covariate and the patient as a random effect.

Time frame:
Day 21
Reported as:
Least squares mean · Litres
Peak and Trough (24 h Post Dose) Forced Expiratory Volume in 1 Second (FEV1) and Forced Vital Capacity (FVC)
LitresNVA237Placebo
FEV1 at peak, Day 211.60 (1.56 to 1.64)1.35 (1.31 to 1.39)
FEV1 at trough, Day 211.44 (1.40 to 1.48)1.33 (1.29 to 1.37)
FVC at peak, Day 213.37 (3.30 to 3.44)3.00 (2.93 to 3.06)
FVC at trough, Day 213.17 (3.11 to 3.23)2.96 (2.90 to 3.02)
SecondarySlow Vital Capacity (SVC) and Total Lung Capacity (TLC)

Vital Capacity is the amount of air that can be forcibly exhaled from the lungs after a full inhalation. Slow Vital Capacity (SVC) test is performed by having the patient slowly and completely blow out all of the air from their lungs. Total Lung Capacity (TLC) is the best vital capacity plus residual volume. Whole body plethysmography (Bodybox) was used to measure SVC and TLC. The trough effects of Day 1 treatment are derived from values prior to morning dosing on the next treatment day (Day 2 of the corresponding period).

Time frame:
Day 21
Reported as:
Least squares mean · Litres
Slow Vital Capacity (SVC) and Total Lung Capacity (TLC)
LitresNVA237Placebo
SVC at trough, Day 21 (n= 98, 96)3.21 (3.14 to 3.27)3.14 (3.07 to 3.21)
SVC at peak, Day 21 (n= 97, 96)3.40 (3.33 to 3.47)3.14 (3.07 to 3.21)
TLC at trough, Day 21 (n= 98, 96)6.99 (6.88 to 7.09)7.17 (7.07 to 7.28)
TLC at peak, Day 21 (n= 97, 96)6.86 (6.75 to 6.97)7.10 (6.99 to 7.21)
SecondarySpecific Airways Conductance (SGaw)

SGaw is a measure of how hard it is to get air into the lungs, measured by (Sec(-1)\*kP). Whole body plethysmography (Bodybox) was used to measure SGaw. The analysis-of covariance model included the sequence, period, and treatment as fixed factors, the baseline value as covariate and the patient as a random effect.

Time frame:
Day 21
Reported as:
Least squares mean · litres/(Second*kpa); kpa = kilopascal
Specific Airways Conductance (SGaw)
litres/(Second*kpa); kpa = kilopascalNVA237Placebo
SGaw at trough, Day 21 (n= 98, 96)0.48 (0.45 to 0.51)0.40 (0.38 to 0.43)
SGaw at peak, Day 21 (n= 97, 96)0.66 (0.63 to 0.70)0.42 (0.39 to 0.46)
SecondaryExertional Dyspnea (Borg CR10 Scale) During Sub-maximal Constant-load Cycle Ergometry Test (SMETT) After 3 Weeks Treatment

The Borg CR10 Scale consists of 12-point score that the patients pointed to so as to indicate their level of dyspnea before and during exercise testing (where 0 indicates no breathlessness at all and 12 indicates maximum breathlessness). A reduction in this score indicates an improvement. The analysis-of covariance model included the sequence, period, and treatment as fixed factors, the baseline value as covariate and the patient as a random effect.

Time frame:
Day 21
Reported as:
Least squares mean · units on a scale
Exertional Dyspnea (Borg CR10 Scale) During Sub-maximal Constant-load Cycle Ergometry Test (SMETT) After 3 Weeks Treatment
units on a scaleNVA237Placebo
Exertional Dyspnea (Borg CR10 Scale) During Sub-maximal Constant-load Cycle Ergometry Test (SMETT) After 3 Weeks Treatment5.64 (5.05 to 6.23)6.80 (6.20 to 7.39)
SecondaryLeg Discomfort (Borg CR10 Scale) During Sub-maximal Constant-load Cycle Ergometry Test (SMETT) After 3 Weeks Treatment

The modified Borg CR10 Scale consists of 12-point score that the patients pointed to so as to indicate their level of leg discomfort before and during exercise testing (where 0 indicates no breathlessness at all and 12 indicates maximum breathlessness). A reduction in this score indicates an improvement. The analysis-of covariance model included the sequence, period, and treatment as fixed factors, the baseline value as covariate and the patient as a random effect.

Time frame:
Day 21
Reported as:
Least squares mean · units on a scale
Leg Discomfort (Borg CR10 Scale) During Sub-maximal Constant-load Cycle Ergometry Test (SMETT) After 3 Weeks Treatment
units on a scaleNVA237Placebo
Leg Discomfort (Borg CR10 Scale) During Sub-maximal Constant-load Cycle Ergometry Test (SMETT) After 3 Weeks Treatment6.21 (5.67 to 6.76)7.05 (6.51 to 7.60)
SecondaryExercise Endurance Time During a Sub-maximal Constant-load Cycle Ergometry Test (SMETT) on Treatment Day 1

SMETT is an exercise procedure where the patient cycles at 80% of the maximum workload (Wmax )value achieved at the Incremental exercise test. During this test, the patient will cycle at a constant load. Exercise endurance time was from commencement of loaded pedaling to stopping exercise. The analysis-of covariance model included the sequence, period, and treatment as fixed factors, the baseline value as covariate and the patient as a random effect.

Time frame:
Day 1
Reported as:
Least squares mean · Seconds
Exercise Endurance Time During a Sub-maximal Constant-load Cycle Ergometry Test (SMETT) on Treatment Day 1
SecondsNVA237Placebo
Exercise Endurance Time During a Sub-maximal Constant-load Cycle Ergometry Test (SMETT) on Treatment Day 1490.92 (458.45 to 523.38)447.78 (415.09 to 480.48)

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
NVA237—1/102 (1%)0/102 (0%)
Placebo—0/102 (0%)0/102 (0%)
Most frequent serious events
Most frequent serious events
EventNVA237Placebo
Intervertebral disc protrusionMusculoskeletal and connective tissue disorders1/1020/102

Baseline characteristics

Age Continuous
Age Continuous(years)NVA237 Followed by PlaceboPlacebo Followed by NVA237Total
Mean61.3 ± 8.5059.7 ± 8.7860.5 ± 8.64
Sex: Female, Male
Sex: Female, Male(Participants)NVA237 Followed by PlaceboPlacebo Followed by NVA237Total
Female252045
Male303363
08

Study locations

10 sites
  • Spartanburg Medical Research, 485 Simuel Road
    Spartanburg, South Carolina 29303, United States
  • Novartis Investigative Site
    Berlin, Germany
  • Novartis Investigative Site
    Frankfurt, Germany
  • Novartis Investigative Site
    Mainz, Germany
  • Novartis Investigative Site
    Mannheim, Germany
  • Novartis Investigative Site
    Wiesbaden, Germany
  • Novartis Investigative Site
    Woehrendamm, Germany
  • Novartis Investigative Site
    Verona, Italy
  • Novartis Investigative Site
    Bucharest, Romania
  • Novartis Investigative Site
    Manchester, United Kingdom
09

References and documents

Publications

  • Beeh KM, Singh D, Di Scala L, Drollmann A. Once-daily NVA237 improves exercise tolerance from the first dose in patients with COPD: the GLOW3 trial. Int J Chron Obstruct Pulmon Dis. 2012;7:503-13. doi: 10.2147/COPD.S32451. Epub 2012 Jul 31. PubMed 22973092 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2010, a primary completion of Feb 2011 and a completion of Feb 2011. It does not say whether these dates are actual or estimated.

Results were first posted in May 2012, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 29, 2010
First posted
Jun 30, 2010
Start
Jun 2010
Primary completionActual
Feb 2011
CompletionActual
Feb 2011
Results first posted
May 7, 2012
Last update
May 7, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 7, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01154127
Responsible party
Sponsor
First posted
Jun 30, 2010
Start date
Jun 2010
Primary completion
Feb 2011
Completion
Feb 2011
Results posted
May 7, 2012
Last update
May 7, 2012

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Glycopyrrolate

Start the discussion